cagrisema phase 3 results 2025 obesity cagrilintide semaglutide Novo Nordisk's experimental drug shows blood pressure benefits Novo Nordisk shares plunge after
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints Reuters HCPLive CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss to placebo in adults with obesity or overweight and T2D in the Phase Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth CagriSema in Adults With or Without Diabetes REDEFINE 1 & 2 Cagrilintide 2.4 mg + Semaglutide 2.4 mg once weekly 20.4% weight loss (non diabetic) & 13.7% (T2D) CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure Nature Metabolism CagriSema Outperforms Semaglutide Alone Across Phase 3 REIMAGINE Trials HCPLive
Pay in 4 interest-free payments of $6.37 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17




